TNF-.alpha.inhibitor
    2.
    发明授权
    TNF-.alpha.inhibitor 失效
    TNF-α抑制剂

    公开(公告)号:US5886010A

    公开(公告)日:1999-03-23

    申请号:US875056

    申请日:1997-07-03

    CPC classification number: A61K31/4704

    Abstract: A method for the prophylaxis and treatment of diseases induced by accelerated INF-.alpha. secretion, such as rheumatoid arthritis, endotoxin shock, adult respiratory distress syndrome, thermal burn, asthma, myocardial infarction, acute phase of viral myocardiosis, etc. which comprises administering a carbostyril compound of the formula: ##STR1## wherein R.sup.1 is H or lower alkyl, and R.sup.2 is phenyl(lower)alkyl having optionally 1 to 3 lower alkoxy substituents on the phenyl ring, or a pharmaceutically acceptable salt thereof to a subject.

    Abstract translation: PCT No.PCT / JP95 / 02592 Sec。 371日期1997年7月3日 102(e)日期1997年7月3日PCT 1995年12月18日PCT PCT。 WO96 / 21447 PCT出版物 日期1996年7月18日预防和治疗由加速的INF-α分泌引起的疾病的方法,如类风湿性关节炎,内毒素休克,成人呼吸窘迫综合征,热灼伤,哮喘,心肌梗死,病毒性心肌病急性期等 其包括施用下式的喹诺酮化合物:其中R 1是H或低级烷基,并且R 2是在苯环上具有任选1至3个低级烷氧基取代基的苯基(低级)烷基,或其药学上可接受的 其盐。

    Carton applicable as display package
    4.
    发明授权
    Carton applicable as display package 失效
    纸箱适用于显示包装

    公开(公告)号:US5722584A

    公开(公告)日:1998-03-03

    申请号:US758050

    申请日:1996-11-27

    Applicant: Jiro Fujiwara

    Inventor: Jiro Fujiwara

    CPC classification number: B65D5/48014 B65D5/5445

    Abstract: A carton including a front wall, a rear wall, a right and a left side walls, a bottom wall and a top wall. A longitudinal partition flap is formed by cutting an approximately central portion of the front wall in a U shape. A partition wall of a cross in a plan view consisting of a lateral partition wall, a longitudinal partition wall and the longitudinal partition flap is integrally provided inside the carton. Each side wall has a perforated cut line continuous with an outer end of the perforated tear part formed at each side of the U-shaped cutout. Contents in the carton are exposed and displayed by removing an upper part of the carton along the perforated tear part. The contents are supported by the cross-shaped partition wall and therefore prevented from lying even when decreased in number.

    Abstract translation: 包括前壁,后壁,右侧和左侧壁,底壁和顶壁的纸箱。 通过将前壁的大致中央部分切割成U形而形成纵向分隔片。 在纸箱内部一体地设置有由横向隔壁,纵向隔壁和纵向隔板构成的俯视图中的十字架的隔壁。 每个侧壁具有与形成在U形切口的每一侧处的穿孔撕裂部的外端连续的穿孔切割线。 通过沿着穿孔的撕裂部分移除纸板箱的上部来暴露和显示纸箱中的内容。 内容物由十字形分隔壁支撑,因此即使在数量减少的情况下也防止其放置。

    Aqueous 6-�3-(3,4-dimethoxybenzyl)-amino-2-hydroxypropoxy! carbostyril
composition
    5.
    发明授权
    Aqueous 6-�3-(3,4-dimethoxybenzyl)-amino-2-hydroxypropoxy! carbostyril composition 失效
    6- [3-(3,4-二甲氧基苄基) - 氨基-2-羟基丙氧基]喹诺酮组合物

    公开(公告)号:US5686440A

    公开(公告)日:1997-11-11

    申请号:US407027

    申请日:1995-03-28

    CPC classification number: A61K47/12 A61K31/47 A61K31/4704 A61K9/0019

    Abstract: This invention provides an aqueous composition wherein a hardly water-soluble active compound, 6-�3-(3,4-dimethoxybenzyl)amino-2-hydroxypropoxy!carbostyril or a salt thereof is dissolved in water in an effective amount, particularly in an amount sufficient for exhibiting the pharmacological activities, by using as a solubilizer DL-lactic acid.

    Abstract translation: PCT No.PCT / JP94 / 01222 Sec。 371日期:1995年3月28日 102(e)1995年3月28日PCT PCT 1994年7月25日PCT公布。 公开号WO95 / 03802 日期1995年2月9日本发明提供一种水性组合物,其中将几乎不溶于水的活性化合物6- [3-(3,4-二甲氧基苄基)氨基-2-羟基丙氧基]喹诺酮或其盐溶于水中, 用量,特别是足以显示药理活性的量,作为增溶剂DL-乳酸。

    Antiarrhythmic agent
    6.
    发明授权
    Antiarrhythmic agent 失效
    抗心律失常药

    公开(公告)号:US5654317A

    公开(公告)日:1997-08-05

    申请号:US403891

    申请日:1995-03-17

    CPC classification number: A61K31/4704 A61K31/47

    Abstract: An antiarrhythmic agent which comprises as an active ingredient a carbostyril derivative of the formula: ##STR1## wherein R.sub.1 is hydrogen atom or a lower alkyl group, and R.sub.2 is a phenyl-lower alkyl group which has optionally 1 to 3 substituents of a lower alkoxy group on the phenyl ring, or a pharmaceutically acceptable salt thereof.

    Abstract translation: PCT No.PCT / JP93 / 01294 Sec。 371日期1995年3月17日 102(e)1995年3月17日PCT 1993年9月10日PCT公布。 出版物WO94 / 06427 日期:1994年3月31日一种抗心律失常药,其包含下式的喹诺酮衍生物作为活性成分:其中R1是氢原子或低级烷基,R2是具有任选的苯基 - 低级烷基 苯基环上1至3个低级烷氧基的取代基,或其药学上可接受的盐。

    Agent for treating thrombosis and phosphodiesterase inhibitor
    7.
    发明授权
    Agent for treating thrombosis and phosphodiesterase inhibitor 失效
    治疗血栓形成和磷酸二酯酶抑制剂的药剂

    公开(公告)号:US5401754A

    公开(公告)日:1995-03-28

    申请号:US208803

    申请日:1994-03-11

    CPC classification number: C07D215/227 A61K31/47

    Abstract: A pharmaceutical preparation comprising at least one compound selected from the group consisting of carbostyril derivatives having the general formula: ##STR1## wherein R.sup.1 is hydrogen or a lower alkyl group optionally having hydroxy group as a substituent; R.sup.2 is a phenyl(lower alkyl) group optionally having 1 to 3 substituents selected from the group consisting of a lower alkoxy group and a halogen atom on the phenyl ring, pyridyl(lower alkyl) group, or a group of the formula --A--NR.sup.3 R.sup.4 (wherein A is a lower alkylene group, R.sup.3 and R.sup.4 are the same or different and represent a lower alkyl group or phenyl group), and a salt thereof, which is useful as an agent for treating thrombosis, more particularly, as an agent for inhibiting platelet aggregation and as an agent for platelet aggregate dissociation.

    Abstract translation: 一种药物制剂,其包含至少一种选自具有以下通式的喹诺酮衍生物的化合物:其中R 1为氢或任选具有羟基作为取代基的低级烷基; R2是任选具有1〜3个选自苯环上的低级烷氧基和卤素原子的取代基的苯基(低级烷基),吡啶基(低级烷基)或式-A- NR3R4(其中A为低级亚烷基,R3和R4相同或不同,表示低级烷基或苯基)及其盐,其可用作治疗血栓形成的药剂,更特别是作为药剂 用于抑制血小板聚集和作为血小板聚集体解离的药剂。

    Benzoheterocyclic compounds
    8.
    发明授权
    Benzoheterocyclic compounds 失效
    苯并杂环化合物

    公开(公告)号:US5290934A

    公开(公告)日:1994-03-01

    申请号:US711273

    申请日:1991-06-04

    Abstract: Novel 4-oxoquinoline-3-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 is cyclopropyl which may have 1 to 3 substituents of alkyl and halogen; phenyl which may be substituted by 1 to 3 substituents of alkoxy, halogen and OH; alkyl which may be substituted by halogen, alkanoyloxy or OH; alkenyl; or thienyl, R.sup.2 is 5- to 9-membered saturated or unsaturated heterocyclic ring which may be substituted, R.sup.3 is alkyl, R is H or alkyl, and X is halogen, and pharmaceutically acceptable salts thereof, said compounds having excellent antimicrobial activity and hence being useful as an antimicrobial agent, and a pharmaceutical composition containing said compound as an active ingredient.

    Abstract translation: 具有下式的新型4-氧代喹啉-3-羧酸化合物:其中R 1是可以具有1至3个烷基和卤素取代基的环丙基; 可被1至3个烷氧基,卤素和OH取代基取代的苯基; 可被卤素,烷酰氧基或OH取代的烷基; 烯基; 或噻吩基,R 2为可被取代的5至9元饱和或不饱和杂环,R 3为烷基,R为H或烷基,X为卤素及其药学上可接受的盐,所述化合物具有优异的抗微生物活性,因此 可用作抗微生物剂,以及含有所述化合物作为活性成分的药物组合物。

    Benzoheterocyclic compounds
    9.
    发明授权
    Benzoheterocyclic compounds 失效
    苯并杂环化合物

    公开(公告)号:US4874764A

    公开(公告)日:1989-10-17

    申请号:US63401

    申请日:1987-06-18

    CPC classification number: C07D215/56 C07D401/04 C07D405/12 C07D487/04

    Abstract: Novel 4-oxoquinoline-3-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.3 is C.sub.1 -C.sub.6 alkyl and R.sup.F is C.sub.1 -C.sub.6 alkyl, and a pharmaceutically acceptable salts thereof, said compounds having excellent antimicrobial activity and hence being useful as an antimicrobial agent, and a pharmaceutical composition containing said compound as an active ingredient.

    Abstract translation: 具有下式的新颖的4-氧代喹啉-3-羧酸化合物:其中R 3是C 1 -C 6烷基且RF是C 1 -C 6烷基,其药学上可接受的盐,所述化合物具有优异的抗微生物活性,因此 可用作抗微生物剂,以及含有所述化合物作为活性成分的药物组合物。

    Tetrazole derivatives, anti-ulcer composition containing the same and
method for treating ulcers
    10.
    发明授权
    Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers 失效
    四唑衍生物,含有其的抗溃疡组合物和治疗溃疡的方法

    公开(公告)号:US4540703A

    公开(公告)日:1985-09-10

    申请号:US333806

    申请日:1981-12-23

    CPC classification number: C07D257/04

    Abstract: Tetrazole derivatives of the formula: ##STR1## wherein R.sup.1 is an optional defined substituent; A is sulfur or a lower alkylene-thio; l is 0 or 1; B is a lower alkylene; R.sup.2 is hydroxy, a lower alkoxy, or a group: ##STR2## wherein R.sup.3 and R.sup.4 are optional defined substituents, or the R.sup.3 and R.sup.4 may combine together with the nitrogen atom to which they are joined to form a defined heterocyclic group, and a pharmaceutically acceptable salt thereof, which have prophylactic or therapeutic activities against peptic and/or duodenal ulcers and also anti-inflammatory activity and are useful as an anti-ulcer or anti-inflammatory drug; processes for the preparation of the tetrazole derivatives; and pharmaceutical composition containing said tetrazole derivatives.

    Abstract translation: 下式的四唑衍生物:其中R 1是任选的限定取代基; A是硫或低级亚烷基 - 硫基; l为0或1; B是低级亚烷基; R 2是羟基,低级烷氧基或基团:其中R 3和R 4是任选的定义的取代基,或者R 3和R 4可以与它们连接的氮原子一起形成定义的杂环基,和 其药学上可接受的盐具有针对消化性溃疡和/或十二指肠溃疡以及抗炎活性的预防或治疗活性,并且可用作抗溃疡或抗炎药物; 制备四唑衍生物的方法; 和含有所述四唑衍生物的药物组合物。

Patent Agency Ranking